- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Endometrial cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1117KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 601KB)
Dostarlimab – March 2022
Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
Last updated
30 May 2025